Combination treatment for colorectal cancer with liver spread
Treatments studied
Part of Cancer clinical trials.
This study tests a new combination of two drugs (AK112 and VG2025) for people with colorectal cancer that has spread to the liver and has not responded to standard treatments. The goal is to see if this combination is safe and can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have colorectal cancer that has spread to the liver and cannot be removed with surgery.
- You have already tried one or two standard treatments, and the cancer has gotten worse.
- Your cancer is the adenocarcinoma type, and genetic tests show it does not have RAS or BRAF mutations.
- You have not had certain types of immunotherapy (like PD-1 or PD-L1 inhibitors) in the past.
- You are in generally good health (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of treatments for advanced colorectal cancer that has spread to the liver. It aims to see if this combination can shrink tumors and help patients live longer.
This trial is testing a combination of a new immunotherapy drug (QL1706) with chemotherapy and either cetuximab or bevacizumab for people with colorectal cancer that has spread to the liver and can potentially be removed by surgery. The goal is to shrink the tumors before surgery, making them easier to remove.
This trial tests a combination of treatments for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It uses an oncolytic virus (which infects and kills cancer cells) along with radiation, chemotherapy, targeted therapy, and immunotherapy to try to shrink the liver tumors.
This trial tests a new combination of drugs for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It aims to shrink or control these liver tumors.
This trial tests a combination of two targeted drugs (sintilimab and bevacizumab) with chemotherapy for people whose colorectal cancer has not spread to the liver. It aims to see if this combo helps control the cancer better after the first treatment stops working.
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
Hear when a new Colorectal Cancer With Hepatic Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.